Biomanufacturing stem cell-derived islets to treat diabetes in custom cell culture vessels

生物制造干细胞衍生的胰岛，在定制细胞培养容器中治疗糖尿病

• 批准号: 576853-2022
• 负责人: Hoesli, CorinneCA
• 金额: $ 6.92万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=747033
• 关键词: Biomanufacturing; stem; cell; derived; islets

Canada is a worldwide leader in islet transplantation for the treatment of type 1 diabetes. The therapy consists in replacing the insulin-producing cells of the pancreas, rather than relying on insulin injections for blood glucose control. Despite the exquisite blood glucose that can be achieved, the therapy is not accessible to most people with type 1 diabetes. The main challenges are insufficient donor islet supply and the need for lifelong immune suppression after transplantation. In other projects, we are developing encapsulation devices to avoid the need for immunosuppression. In the current project, we aim to improve therapeutic cell supply by partnering with Saint-Gobain Life Sciences to mass produce stem cell-derived islets. Saint-Gobain manufactures fluoropolymer bags with high oxygen permeability which offer several advantages over other culture systems. The use of bags as bioreactor facilitates scale-up and automation. Handling of cells through closed circuits can reduce the risks of introducing bacteria or viruses into cultures. Together, we will develop bags that are tailored to challenging stem cell cultures and pancreatic differentiation. Ultimately, these tailored bags could be implemented at clinics or biomanufacturing sites in Canada to reliably produce islets and other therapeutic organoids from stem cells.

加拿大在治疗 1 型糖尿病的胰岛移植方面处于世界领先地位。该疗法包括替换胰腺中产生胰岛素的细胞，而不是依靠注射胰岛素来控制血糖。尽管可以达到极好的血糖水平，但大多数 1 型糖尿病患者无法接受这种治疗。主要挑战是供体胰岛供应不足以及移植后需要终生免疫抑制。在其他项目中，我们正在开发封装装置以避免免疫抑制的需要。在当前的项目中，我们的目标是通过与圣戈班生命科学公司合作大规模生产干细胞衍生的胰岛来改善治疗细胞供应。圣戈班生产具有高透氧性的含氟聚合物袋，与其他培养系统相比具有多种优势。使用袋子作为生物反应器有利于规模化和自动化。通过闭路处理细胞可以降低将细菌或病毒引入培养物的风险。我们将共同开发专为具有挑战性的干细胞培养和胰腺分化而设计的袋子。最终，这些定制的袋子可以在加拿大的诊所或生物制造基地使用，以可靠地从干细胞生产胰岛和其他治疗性类器官。